TGA grant provisional approval to Novavax COVID-19 vaccine

On January 19, 2022 Australia’s Therapeutic Goods Administration (TGA) granted provisionally registration for Biocelect Pty Ltd’s (on behalf of Novavax Inc) COVID-19 vaccine NUVAXOVID.  This protein sub-unit vaccine is for active immunisation to prevent COVID-19 in individuals 18 years of age and older and is recommended as 2 doses administered 3 weeks apart.

This a protein subunit vaccine administering a set dose of spike-antigen (SARS-CoV-2 rS  or NVX-CoV-2373) compared to the genetic vaccines which deliver a genetic code (mRNA or DNA) which will trick the body into manufacturing unknown quantities of foreign spike-protein antigen.

The product has been under evaluation since February 2021

Australia purchased 51 million doses of Novavax and by September 2022 less than 1% has been used!